The dose-ranging trial conducted in 286 patients with ASCVD history demonstrated a mean 80% reduction of Lp(a) at the highest dose, while 98% of patients reached the desirable level of 50 mg/dl (Table 1) [29▪▪,30▪]. This evidence concerns the gene LPA and atherosclerosis.